Iterum Therapeutics PLC (ITRMF) intrinsic value & 10-year financials
Iterum Therapeutics PLC (ITRMF) has a Graham intrinsic value of $149.49 per share.
- Graham intrinsic value
- $149.49
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $197
- Revenue (FY2024)
- —
- Revenue growth (10-yr CAGR)
- -73.0%
- ROIC (10-yr avg)
- -509.8%
- Free cash flow (FY2024)
- -$26.8M
ITRMF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -$24.8M | -$1.26 | -$26.8M | — | -1713.7% |
| FY2023 | — | -$38.4M | -$2.96 | -$39.3M | — | -543.4% |
| FY2022 | — | -$44.4M | -$3.63 | -$18.5M | — | -114.5% |
| FY2021 | $0 | -$91.6M | -$8.41 | -$15.9M | — | -1318.5% |
| FY2020 | $0 | -$52.0M | -$4.64 | -$54.5M | — | 153.3% |
| FY2019 | $37.0K | -$103.1M | — | -$78.9M | -275732.4% | -673.3% |
| FY2018 | $869.0K | -$77.1M | — | -$76.0M | -8810.0% | -212.1% |
| FY2017 | $508.0K | -$29.4M | — | -$31.4M | -5798.2% | -95.0% |
| FY2016 | $0 | -$13.5M | — | — | — | -71.0% |
| FY2015 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Iterum Therapeutics plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Iterum Therapeutics plc has historically struggled to out-earn its cost of capital, averaging just -36.0% ROIC.
Iterum Therapeutics plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Iterum Therapeutics plc is modeled at -73.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $149.49 per share.